SGEN
$169.50
Seagen
($3.70)
(2.14%)
SGEN
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.74)
Revenue:  $407.59 Mil
Thursday
Jan 27
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Thursday, October 28, 2021

What do you expect when SGEN reports earnings?
Beat
Meet
Miss

Where is SGEN's stock price going from here?
Up
Flat
Down
Stock chart of SGEN
Analysts
Summary of analysts' recommendations for SGEN
Score
Grade
Pivots
Resistance
$185.74
$182.32
$175.91

$172.48

Support
$166.07
$162.65
$156.24
Tweet
Growth
Description
Seagen Inc. is a biotechnology company. It discovers, develops and commercializes transformative cancer medicines. The company operates principally in California, Canada, Switzerland and the European Union. Seagen Inc., formerly known as Seattle Genetics Inc., is headquartered in the Seattle.
Peers
BiogenNeurocrine BiosciencesAmgenGilead SciencesBluebird BioBioCryst PharmaceuticalsRepligenSangamo TherapeuticsBio-TechneNovavax